CRISPR

On November 21, shares rose CRISPR therapeutics (NASDAQ: CRSB) Prices fell by 47% from their peak in March. This may be a bit surprising to people who follow this developer of gene therapies. After all, it's been less than a year…

Bill Oxford/iStock via Getty Images Following the recent FDA green light for the gene therapy Casgevy, "it is unlikely" that approval of a similar product will take place "any time soon," according to a report by GlobalData. According…

© Reuters. Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring…

room mom Scribe Therapeutics is partnering with the Eli Lilly unit (New York Stock Exchange: LLYTherapeutics prevail and grant rights to CRISPR X-Editing (XE) technologies to develop in vivo treatments for neuromuscular diseases. Under…